R1 RCM - RCM Stock Forecast, Price & News

R1 RCM Inc. provides technology-driven solutions that transform the patient experience and financial performance of hospitals, health systems, and medical groups. It offers end-to-end revenue cycle management (RCM) services, which address the spectrum of revenue cycle challenges faced by healthcare providers. The company also provides modular services, including physician advisory services, which assists healthcare organizations in complying with payer requirements regarding whether to classify a hospital visit as an in-patient or an out-patient observation case for billing purposes; practice management services that offers administrative and operational support for patient care and outsource non-core functions; revenue integrity solutions, including charge capture, charge description master maintenance, and pricing services; coding management services, such as business intelligence and analysis, human capital management, accountability framework, and quality management programs; patient experience; and business office services. In addition, the company offers software-as-a-service based scheduling and patient access solutions. The company was founded in 2003 and is headquartered in Murray, Utah.

R1 RCM Trading Down 0.8 %

R1 RCM stock traded down $0.20 during midday trading on Thursday, reaching $25.85. The stock had a trading volume of 24,610 shares, compared to its average volume of 1,247,677. R1 RCM has a twelve month low of $18.71 and a twelve month high of $27.86. The stock has a market capitalization of $7.23 billion, a PE ratio of 144.73, a price-to-earnings-growth ratio of 6.08 and a beta of 0.91. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.54 and a current ratio of 1.57. The stock's 50-day simple moving average is $22.62 and its 200 day simple moving average is $23.79.

R1 RCM (NASDAQ:RCM - Get Rating) last issued its earnings results on Monday, May 9th. The healthcare provider reported $0.09 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). R1 RCM had a net margin of 3.98% and a return on equity of 12.72%. The firm had revenue of $385.70 million during the quarter, compared to analyst estimates of $384.18 million. During the same quarter in the previous year, the business posted ($2.37) EPS. R1 RCM's revenue was up 12.6% compared to the same quarter last year. Analysts expect that R1 RCM will post 0.23 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on RCM. Deutsche Bank Aktiengesellschaft increased their target price on R1 RCM from $26.00 to $31.00 in a research note on Thursday, August 4th. TheStreet raised R1 RCM from a "d" rating to a "c" rating in a research note on Monday, May 9th. JPMorgan Chase & Co. assumed coverage on R1 RCM in a research note on Monday, August 1st. They issued an "overweight" rating for the company. Guggenheim assumed coverage on R1 RCM in a research note on Wednesday, April 13th. They issued a "neutral" rating for the company. Finally, Barclays reaffirmed an "overweight" rating and issued a $29.00 price objective on shares of R1 RCM in a research note on Wednesday, June 29th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, R1 RCM has an average rating of "Moderate Buy" and a consensus target price of $30.17.